NZ611947A - Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors - Google Patents

Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors

Info

Publication number
NZ611947A
NZ611947A NZ611947A NZ61194707A NZ611947A NZ 611947 A NZ611947 A NZ 611947A NZ 611947 A NZ611947 A NZ 611947A NZ 61194707 A NZ61194707 A NZ 61194707A NZ 611947 A NZ611947 A NZ 611947A
Authority
NZ
New Zealand
Prior art keywords
plus
corticosteroid
treating tumors
corticosteroids
corticosteroid chemotherapeutic
Prior art date
Application number
NZ611947A
Inventor
Judith Oprins
Paul Parren
Ole Baadsgaard
Yvo Graus
Steen Lisby
Jan Van De Winkel
Michel De Weers
Vugt Martine Van
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of NZ611947A publication Critical patent/NZ611947A/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Discloses a therapeutic composition comprising a non-agonistic antibody which binds to CD38, at least one corticosteroid, and at least one non-corticosteroid chemotherapeutic agent. Also disclosed is the use of a non-agonistic antibody which binds CD38, at least one corticosteroid and at least one non-corticosteroid, in the manufacture of a medicament for the treatment of a patient with cancer involving cells expressing CD38, with a dosing regime comprising at least one dosing cycle that is designed to provide the effective delivery of the medicament over 4 weeks, wherein the dosing cycle is repeated for as long as necessary to achieve the desired biological response in the patient.
NZ611947A 2006-09-26 2007-09-26 Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors NZ611947A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200601232 2006-09-26
NZ59735707 2007-09-26

Publications (1)

Publication Number Publication Date
NZ611947A true NZ611947A (en) 2015-01-30

Family

ID=52464885

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ611947A NZ611947A (en) 2006-09-26 2007-09-26 Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors

Country Status (1)

Country Link
NZ (1) NZ611947A (en)

Similar Documents

Publication Publication Date Title
NZ576122A (en) Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
MX2007003795A (en) Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases.
NZ604029A (en) Methods of treating bladder cancer
MY151449A (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2010003815A (en) Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent.
BRPI0906181A2 (en) "method for treating hyperproliferative dysfunction, pharmaceutical composition, use of a therapeutic combination in the manufacture of a medicament for treating cancer, article of manufacture for treating a hyperproliferative dysfunction, method for determining compounds to be used in combination for the treatment of cancer". cancer treatment and method for determining a therapeutic combination to be used for cancer treatment "
HK1123186A1 (en) Combination of zd6474 and pemetrexed zd6474
MX2007003505A (en) Combination comprising zd6474 and an imatinib.
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
MX353964B (en) Therapeutic agents and uses thereof.
MX2011013424A (en) Method of treating cancer with dll4 antagonist and chemotherapeutic agent.
HK1123976A1 (en) Combination of azd2171 and pemetrexed azd2171
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
MXPA05008583A (en) Combination therapy of zd6474 with 5-fu or/and cpt-11.
IL177953A0 (en) Combination therapy including azd2171 and a taxane
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine
MX2018015916A (en) Porphyrin compounds and compositions useful for treating cancer.
NZ611947A (en) Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
IL307842A (en) Methods and compositions for treating glioblastoma
NZ602407A (en) Cd37 immunotherapeutic combination therapies and uses thereof
UA95797C2 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
WO2009140572A3 (en) Combinatorial treatment with glucose regulated protein-170 and melanoma differentiation associated gene-7

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 26 SEP 2017 BY WATERMARK PATENT AND TRADE MARKS ATTORNEYS

Effective date: 20150505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2018 BY CPA GLOBAL

Effective date: 20170810

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2019 BY CPA GLOBAL

Effective date: 20180809

S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
S38C Proceedings under section 38 (amendment of specification with leave of commissioner): specification amended
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2020 BY CPA GLOBAL

Effective date: 20190815

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2021 BY CPA GLOBAL

Effective date: 20200813

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2022 BY CPA GLOBAL

Effective date: 20210812

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2023 BY CPA GLOBAL

Effective date: 20220811

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 SEP 2024 BY CPA GLOBAL

Effective date: 20230811